Shares of Qiagen (QGEN) trading in New York are up $4.89, or 10%, to $52.46 after Bloomberg reported that the European molecular testing company is weighing strategic options, including a potential sale.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen trading halted, volatility trading pause
- Qiagen studying possible sale, Bloomberg says
- Goldman Sachs Discloses 3.6% Voting Stake in Qiagen
- Qiagen Reports AFM Notification of Major Stake by Massachusetts Financial Services
- Massachusetts Financial Services Discloses Nearly 10% Voting Stake in Qiagen